GPER1 and pancreatic ductal adenocarcinoma: As assessed by GPER antagonist treatments or GPER targeting siRNA transfection, G-1 effects were also described as GPER-independent in pancreatic ductal adenocarcinoma [52], adrenocortical carcinoma [54] and vascular smooth muscle cells [39], whereas the question is still debated in ovarian [41,49] or breast cancer cells (see [60] for review).